Fusion Biopsy Market Size, Share, Trends & Forecast
The Fusion Biopsy Market is expanding as healthcare providers adopt more precise and minimally invasive approaches to tissue sampling and cancer diagnosis. The market was valued at approximately USD 0.85 billion in 2024 and is projected to reach USD 0.92 billion in 2025 and USD 1.91 billion by 2035, registering a 7.65% CAGR from 2025 to 2035.
Advanced imaging is playing an important role in market development, particularly through the integration of MRI and ultrasound guidance. These technologies can improve lesion targeting and support more accurate biopsy procedures. Increasing investment in research and development is also encouraging manufacturers to introduce systems designed to improve procedural efficiency and diagnostic precision.
By tech target, DNA represents the largest segment, while RNA is emerging as a rapidly expanding area. Multi-gene Panels lead the product segment, supported by their use in oncology and precision medicine, while Companion Diagnostics is growing as targeted therapies create greater demand for tests that help identify suitable treatment options.
Oncology is the largest application area, reflecting the increasing need for accurate tumor profiling and cancer diagnosis. By technology, Next-Generation Sequencing (NGS) holds the leading position, while PCR remains important because of its speed and established laboratory use. North America accounts for approximately 45% of the global market, followed by Europe at around 30%, while Asia-Pacific represents about 20% and is expanding rapidly.
Future opportunities are expected to center on AI-assisted imaging, improved MRI-ultrasound fusion, digital diagnostics, and personalized medicine. As healthcare systems increase investment in cancer care and minimally invasive procedures, fusion biopsy technologies that provide precise targeting, efficient workflows, and actionable molecular information are likely to gain broader adoption.